Related Experiment Video
Updated: Sep 25, 2025

Remote Laboratory Management: Respiratory Virus Diagnostics
Published on: April 6, 2019
Development of Evidence-Based COVID-19 Management Guidelines for Local Context: The Methodological Challenges
Sarah Nadeem1,2, Salima Saleem Aamdani1, Bushra Ayub1
1CITRIC Centre for Clinical Best Practices, Aga Khan University, Karachi, Pakistan.
This study highlights challenges in updating COVID-19 treatment guidelines. Corticosteroids are strongly recommended, but tocilizumab evidence conflicts, while antibiotics and ivermectin are not advised for hospitalized patients.
Area of Science:
- Infectious Diseases
- Pharmacology
- Public Health
Background:
- The COVID-19 pandemic created therapeutic challenges due to rapid spread and evolving scientific understanding.
- National and international health organizations continuously updated treatment guidelines, including Pakistan's National Command Operation Center (NCOC).
- Keeping clinical management guidelines current with emerging evidence presents significant global and local challenges.
Purpose of the Study:
- To systematically review pharmacological interventions for hospitalized COVID-19 patients based on NCOC guidelines v4.
- To compare these findings with current World Health Organization (WHO) treatment guidelines (v7.1).
- To identify methodological challenges in updating evidence-based treatment recommendations.
Main Methods:
- Conducted a systematic review of global research on pharmacological treatments for hospitalized COVID-19 patients.
- Focused on interventions included in Pakistan's NCOC national guidelines v4 (December 2020).
- Assessed evidence strength and quality using GRADE methodology and compared findings with WHO COVID-19 pharmacological treatment guidelines v7.1.
Main Results:
- Strong evidence supports corticosteroid use in severe/critical COVID-19 patients, aligning with WHO v7.1.
- Conflicting evidence exists for tocilizumab; NCOC guidelines (v4) showed weak support, while WHO (v7.1) strongly recommends it for severe/critical cases.
- Both the systematic review and WHO v7.1 recommend against using antibiotics and ivermectin for hospitalized COVID-19 patients.
Conclusions:
- Evolving research on COVID-19 treatments necessitates continuous guideline updates.
- This study demonstrates challenges in maintaining up-to-date recommendations, with significant changes observed compared to WHO v7.1.
- Evidence assessment is crucial for adapting pharmacological treatment strategies during the pandemic.
Related Concept Videos
Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
Principles of Disease Surveillance
Steps in Outbreak Investigation
Methods of Documentation VI: Case Management Model
For example, a patient with a chronic...
Methods Of Healthcare Delivery System
Managed Care System:
The managed care system is designed to control the cost while maintaining the quality of care. The patient's care from admission to discharge is planned by the primary care provider or the case manager, also known as the gatekeeper. In a managed care system, the number of care providers is...
Bias in Epidemiological Studies

